A new class of obesity treatments is moving through clinical trials, and if you’re prescribing or managing patients on GLP-1 therapy, it’s worth knowing what’s coming before it reaches the market. Amylin analog weight loss drugs work through a different biological pathway than GLP-1 receptor agonists, and five major companies are developing them right now. There is one already under FDA review; the rest are one to several years behind it.
This article covers what amylin is, how these drugs differ from GLP-1 therapy, and where each pipeline candidate stands today. Every timeline below reflects the forecast at the time of writing and can shift with trial results or regulatory review.
What you will learn in this article:
Amylin is a peptide hormone the pancreas releases alongside insulin after a meal. It signals satiety to the brain, slows gastric emptying, and helps regulate how much food a person eats before feeling full, according to Pharmacy Times. Amylin activates a receptor called AMYR, formed when a calcitonin receptor pairs with one of three receptor activity-modifying proteins. That pathway operates independently of the incretin system GLP-1 drugs rely on.
Amylin analog weight loss drugs are synthetic compounds built to mimic that signaling and hold it active far longer than the body’s own amylin, which clears within minutes. Depending on the molecule, they are dosed weekly, biweekly, or monthly by subcutaneous injection, and several are also being studied as fixed-dose combinations with a GLP-1 or GIP agonist rather than as standalone therapy.
GLP-1 receptor agonists — semaglutide, tirzepatide, and the rest of that class — work through the incretin system, amplifying the gut hormone signaling that regulates insulin secretion and appetite after a meal. Amylin analog weight loss drugs work through amylin and calcitonin receptors instead, a separate satiety pathway.
Two things follow from that distinction. A different receptor pathway means a different adverse event profile is plausible, though early data across amylin candidates shows a gastrointestinal tolerability pattern broadly similar to GLP-1 therapy. And because the pathways are separate, amylin and GLP-1 mechanisms can be combined in a single molecule or fixed-dose product — which is already the basis for the most advanced amylin-pathway drug in the pipeline, described below.
No. As of this writing, no amylin analog weight loss drug has FDA approval. One combination product is under active FDA review, and the rest are in Phase 1 or Phase 2 development. The list below reflects each candidate’s public status and the most recent timeline each company has disclosed. Company guidance on obesity-drug timelines changes often, so treat every date as a forecast rather than a commitment.
Set the timeline honestly. CagriSema is under FDA review and could have a decision this year, but everything else on this list is one to three years from a filing, at minimum, and none has completed the safety and efficacy review that current GLP-1 and GIP therapies have already passed. A patient asking whether to wait for an amylin drug instead of starting or continuing GLP-1 therapy now should hear that trade-off stated plainly: nothing in this pipeline is an available alternative today, and current FDA-approved options remain the evidence-based choice for a patient who is a candidate now.
Where an amylin drug’s stage is relevant is in setting expectations about what happens after approval, not before it. A newly approved amylin monotherapy or amylin/GLP-1 combination will need the same evidence-based integration into practice protocols that any new medication class requires — patient selection, monitoring, and counseling all shift once real-world data starts accumulating.
Providers who want this list kept current without tracking every company’s quarterly pipeline update can rely on the Certified Medical Weight Management Provider Program subscription for that — the training updates when a drug in this class is actually approved, so you know when it’s time to act rather than guessing from press coverage.
What is amylin and what does it do in the body?
Amylin is a peptide hormone released by the pancreas alongside insulin after eating. It signals satiety to the brain and slows gastric emptying, which reduces food intake. Amylin analog weight loss drugs are synthetic compounds designed to activate the same receptor pathway for a longer duration than the body’s natural hormone.
How is an amylin analog different from a GLP-1 drug like semaglutide?
GLP-1 receptor agonists work through the incretin system. Amylin analogs activate amylin and calcitonin receptors instead, a separate pathway that regulates satiety and gastric emptying independently of incretin signaling. Because the pathways are distinct, several companies are developing fixed-dose combinations of the two mechanisms rather than treating them as competing options.
Is any amylin analog weight loss drug FDA-approved?
Not yet. Novo Nordisk’s CagriSema, a combination of cagrilintide and semaglutide, is the closest to approval — its new drug application was filed with the FDA in December 2025, with a decision expected sometime in 2026. Every other candidate covered here is still in Phase 1 to Phase 3 trials.
Which amylin analog weight loss drug is closest to approval?
CagriSema from Novo Nordisk is furthest along and currently under FDA review. Eli Lilly’s eloralintide is the most advanced monotherapy candidate, having entered Phase 3 trials in December 2025, though it does not yet have a filing date. AbbVie’s ABBV-295, AstraZeneca’s AZD6234, and Pfizer’s MET-233i are earlier stage.
Can amylin analog weight loss drugs be combined with GLP-1 or GIP therapy?
Yes, and several programs are built around that combination rather than amylin alone. CagriSema pairs cagrilintide with semaglutide. AstraZeneca is testing AZD6234 alongside its GLP-1/glucagon candidate AZD9550. Pfizer is studying Metsera’s MET-233i both alone and combined with the GLP-1 candidate MET-097i. Lilly has said it is evaluating eloralintide for potential combination use with incretin therapies as well as monotherapy.
What are the side effects of amylin analog weight loss drugs?
Across the candidates with published data, the most common adverse events have been gastrointestinal — nausea, vomiting, and related symptoms — generally mild to moderate and more frequent at higher doses or faster dose escalation. No candidate has completed the long-term safety review required for approval, so this safety profile is preliminary and will be refined as later-phase and post-market data accumulate.
When will amylin analog weight loss drugs be available to prescribe?
CagriSema could reach the market first if its FDA review concludes favorably in 2026. The rest of the field is realistically several years out: Lilly’s eloralintide has no announced filing date following its December 2025 Phase 3 start, and AbbVie, AstraZeneca, and Pfizer’s candidates are all earlier in development. These are forecasts based on public disclosures as of this writing, not commitments from any of the companies involved.
This article is for educational purposes only and is not medical, legal, or regulatory advice. The drugs discussed are investigational except where noted, have not been evaluated or approved by the FDA except as stated, and development timelines are subject to change. Clinical care, including prescribing and monitoring of weight management medications, must be delivered by a licensed prescriber acting within their scope of practice and in accordance with current evidence-based guidelines, FDA labeling, and applicable state and federal law.